Multiple Sclerosis (MS): Symptoms, Types, Diagnosis & Treatment Overview

Multiple Sclerosis: Comprehensive Overview

Pathophysiology

Autoimmune demyelination of CNS (brain, spinal cord, optic nerves) → disrupted nerve conduction. Relapsing inflammation + neurodegeneration.

Clinical Phenotypes (2013 Revision)

  • Relapsing-Remitting (RRMS): 85% onset. Attacks → remission. Active/inactive, worsening/not.
  • Primary Progressive (PPMS): 10–15%. Gradual worsening from onset, no distinct relapses.
  • Secondary Progressive (SPMS): Follows RRMS. Gradual progression ± occasional relapses.
  • Clinically Isolated Syndrome (CIS): First demyelinating event; high MRI lesion load → high MS risk.

Common Symptoms

  • Fatigue (80%), optic neuritis, sensory loss, weakness, spasticity, ataxia, bladder/bowel dysfunction, cognitive impairment, depression, pain, Uhthoff's phenomenon (heat worsening).

Diagnosis (McDonald Criteria 2017)

Dissemination in space (MRI lesions in ≥2 of 4 CNS areas) + time (simultaneous Gd+ & non-enhancing, or new lesion on follow-up) + CSF oligoclonal bands + exclusion of mimics.

Treatment Landscape

  • DMTs (20+): Platform (interferons, glatiramer), high-efficacy (natalizumab, ocrelizumab, ofatumumab, cladribine, alemtuzumab, BTK inhibitors), oral (fingolimod, siponimod, ozanimod, ponesimod, teriflunomide, dimethyl fumarate, diroximel).
  • Acute relapse: IV methylprednisolone 1g × 3–5d ± PLEX.
  • Symptomatic: Dalfampridine (walking), baclofen/tizanidine (spasticity), modafinil (fatigue), anticholinergics (bladder).
  • Rehab: PT, OT, speech, cognitive rehab, vocational.

Prognosis

Normal life expectancy with modern DMTs. Disability accumulation variable. Early high-efficacy therapy improves long-term outcomes. Holistic care essential.

Multiple Sclerosis - Related Articles